-
1
-
-
33846327303
-
-
The Merck Index 13th Edition, Merck Research Laboratories Division of Merck Co. Ind., Whitehouse Station, NJ, 2001
-
The Merck Index 13th Edition, Merck Research Laboratories Division of Merck Co. Ind., Whitehouse Station, NJ, 2001
-
-
-
-
2
-
-
0347757101
-
-
K. L. Hoskin, G. A. Lambert, C. Donaldson, A. S. Zagami, Brain Research 998 (2004) 91
-
(2004)
Brain Research
, vol.998
, pp. 91
-
-
Hoskin, K.L.1
Lambert, G.A.2
Donaldson, C.3
Zagami, A.S.4
-
3
-
-
0347985815
-
-
P. L. Durham, P. X. Dong, K. T. Belasco, J. Kasperski, W. W. Gierasch, L. Edvinsson, D. D. Heistad, F. M. Faraci, A. F. Russo, Brain Research 997 (2004) 103
-
(2004)
Brain Research
, vol.997
, pp. 103
-
-
Durham, P.L.1
Dong, P.X.2
Belasco, K.T.3
Kasperski, J.4
Gierasch, W.W.5
Edvinsson, L.6
Heistad, D.D.7
Faraci, F.M.8
Russo, A.F.9
-
4
-
-
33846300747
-
-
http://www.medicinenet.com/eletriptan/article.htm
-
-
-
-
5
-
-
33846290383
-
-
ICH Q3A(R) Draft Revised Guidance on Impurities in New Drug Substances, Federal Register 65 (140) (2000) 45085
-
ICH Q3A(R) Draft Revised Guidance on Impurities in New Drug Substances, Federal Register 65 (140) (2000) 45085
-
-
-
-
7
-
-
0007890743
-
-
K. M. Alsante, T. D. Hatajik, L. L. Lohr, T. R. Sharp, American Pharmaceutical Review 4 (2001) 70
-
(2001)
American Pharmaceutical Review
, vol.4
, pp. 70
-
-
Alsante, K.M.1
Hatajik, T.D.2
Lohr, L.L.3
Sharp, T.R.4
-
8
-
-
33846318232
-
-
ICH Q3B(R) Draft Revised Guidance on Impurities in New Drug Products, Federal REgister 65 (139) (2000) 44791
-
ICH Q3B(R) Draft Revised Guidance on Impurities in New Drug Products, Federal REgister 65 (139) (2000) 44791
-
-
-
-
9
-
-
0003652422
-
-
2nd edition, Springer, Berlin, Heidelberg
-
H. G. Vogel, Drug Discovery and Evaluation, Pharmacological Assays, 2nd edition, Springer, Berlin, Heidelberg, 2002
-
(2002)
Drug Discovery and Evaluation, Pharmacological Assays
-
-
Vogel, H.G.1
-
11
-
-
33846308562
-
-
ICH Q2B Validation of Analytical Procedures: Methodology, The European Agency for the Evaluation of Medicinal Products, Geneva, 1996
-
ICH Q2B Validation of Analytical Procedures: Methodology, The European Agency for the Evaluation of Medicinal Products, Geneva, 1996
-
-
-
-
13
-
-
0032815096
-
-
J. A. Orwa, K. Vandenbempt, S. Dapuydt, E. Roets, J. Hoogmartens, J. Pharm. biomed. Anal. 20 (1999) 745
-
(1999)
J. Pharm. biomed. Anal
, vol.20
, pp. 745
-
-
Orwa, J.A.1
Vandenbempt, K.2
Dapuydt, S.3
Roets, E.4
Hoogmartens, J.5
-
14
-
-
0035089518
-
-
Y. Vander Heyden, A. Nijhuis, J. Smeyers-Verbeke, B. G. M. Vandeginste, D. L. Massart, J. Pharm. Biomed. Anal. 24 (2001) 723
-
(2001)
J. Pharm. Biomed. Anal
, vol.24
, pp. 723
-
-
Vander Heyden, Y.1
Nijhuis, A.2
Smeyers-Verbeke, J.3
Vandeginste, B.G.M.4
Massart, D.L.5
-
15
-
-
0036681681
-
-
R. Ficarra, M. L. Calabro, P. Cutroneo, S. Tommasini, S. Melardi, M. Semreen, S. Furlanetto, P. Ficarra, G. Altavilla, J. Pharm. Biomed. Anal. 29 (2002) 1097
-
(2002)
J. Pharm. Biomed. Anal
, vol.29
, pp. 1097
-
-
Ficarra, R.1
Calabro, M.L.2
Cutroneo, P.3
Tommasini, S.4
Melardi, S.5
Semreen, M.6
Furlanetto, S.7
Ficarra, P.8
Altavilla, G.9
|